Keith A Rodvold
Overview
Explore the profile of Keith A Rodvold including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
100
Citations
3293
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rodvold K, Gotfried M, Ussery X, Wong S, Hamed K
Antimicrob Agents Chemother
. 2024 Oct;
68(11):e0110324.
PMID: 39352135
SPR720 is a phosphate ester prodrug that is converted rapidly to SPR719, the active moiety, which exhibits potent activity against clinically relevant mycobacterial species including complex (MAC) and . SPR720...
2.
Rodvold K, Shorr A
Am J Respir Crit Care Med
. 2024 Feb;
209(7):777-778.
PMID: 38300143
No abstract available.
3.
Satlin M, van Duin D, Tamma P, Lodise T, Van Tyne D, Rodvold K, et al.
Clin Infect Dis
. 2023 Oct;
77(Suppl 4):S305-S313.
PMID: 37843118
Addressing the treatment and prevention of antibacterial-resistant gram-negative bacterial infections is a priority area of the Antibacterial Resistance Leadership Group (ARLG). The ARLG has conducted a series of observational studies...
4.
Rodvold K, Bader J, Bruss J, Hamed K
Antimicrob Agents Chemother
. 2023 Jun;
67(7):e0042623.
PMID: 37338378
SPR206 is a next-generation polymyxin being developed for the treatment of multidrug-resistant (MDR) Gram-negative infections. This Phase 1 bronchoalveolar lavage (BAL) study was conducted to evaluate SPR206's safety and pharmacokinetics...
5.
Rodvold K, Gotfried M, Gupta V, Ek A, Srivastava P, Talley A, et al.
Antimicrob Agents Chemother
. 2022 Jun;
66(7):e0059022.
PMID: 35762796
Tebipenem pivoxil hydrobromide (TBP-PI-HBr) is an oral carbapenem prodrug being developed for the treatment of serious bacterial infections. The active moiety, tebipenem, has broad-spectrum activity against common pathogens, including extended-spectrum-β-lactamase...
6.
Patel G, Rodvold K, Gupta V, Bruss J, Gasink L, Bajraktari F, et al.
Antimicrob Agents Chemother
. 2022 Apr;
66(5):e0240721.
PMID: 35420493
Tebipenem pivoxil hydrobromide (TBP-PI-HBr) is an oral carbapenem prodrug antimicrobial agent with broad-spectrum activity that includes multidrug-resistant (MDR) . This study evaluated the safety, tolerability, and pharmacokinetics of TBP-PI-HBr in...
7.
Drwiega E, Rodvold K
Clin Pharmacokinet
. 2022 Jan;
61(2):337-338.
PMID: 34982408
No abstract available.
8.
Drwiega E, Rodvold K
Clin Pharmacokinet
. 2021 Oct;
61(1):17-46.
PMID: 34651282
A comprehensive review of drug penetration into pulmonary epithelial lining fluid (ELF) was previously published in 2011. Since then, an extensive number of studies comparing plasma and ELF concentrations of...
9.
Katsube T, Nicolau D, Rodvold K, Wunderink R, Echols R, Matsunaga Y, et al.
J Antimicrob Chemother
. 2021 Sep;
76(11):3069.
PMID: 34532730
No abstract available.
10.
Katsube T, Nicolau D, Rodvold K, Wunderink R, Echols R, Matsunaga Y, et al.
J Antimicrob Chemother
. 2021 Aug;
76(11):2902-2905.
PMID: 34383901
Objectives: Lung penetration of cefiderocol, a novel siderophore cephalosporin approved for treatment of nosocomial pneumonia, has previously been evaluated in healthy subjects. This study assessed the intrapulmonary pharmacokinetic profile of...